Published in Mov Disord on December 15, 2008
Olfactory dysfunction in Parkinson disease. Nat Rev Neurol (2012) 1.73
Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry (2012) 1.44
The applicability of the "Sniffin' Sticks" olfactory test in a Turkish population. Med Sci Monit (2013) 1.03
Olfaction in the psychosis prodrome: electrophysiological and behavioral measures of odor detection. Int J Psychophysiol (2013) 0.85
The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. BMC Neurol (2011) 0.81
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. Neurol Sci (2013) 0.80
Transcranial sonography and the pocket smell test in the differential diagnosis between parkinson's disease and essential tremor. Neurol Sci (2015) 0.79
Diagnostic value of the impairment of olfaction in Parkinson's disease. PLoS One (2013) 0.78
Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression. Behav Neurol (2015) 0.78
Cultural Adaptation of the Portuguese Version of the "Sniffin' Sticks" Smell Test: Reliability, Validity, and Normative Data. PLoS One (2016) 0.76
The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. Mov Disord (2010) 0.75
The predictive value of SS-16 in clinically diagnosed Parkinson's disease patients: comparison with (99m)Tc-TRODAT-1 SPECT scans. Transl Neurodegener (2016) 0.75
Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism Relat Disord (2016) 0.75
Effects of age and cognition on a cross-cultural paediatric adaptation of the Sniffin' Sticks Identification Test. PLoS One (2015) 0.75
Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell (2005) 7.15
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol (2005) 2.94
Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord (2004) 2.84
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study. Mov Disord (2003) 2.69
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol (2009) 2.38
Association between overweight/obesity and periodontitis in adults. A systematic review. Obes Rev (2011) 2.37
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain (2010) 2.19
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02
Retrograde trans-synaptic retinal ganglion cell loss identified by optical coherence tomography. Brain (2009) 1.97
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol (2010) 1.81
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord (2010) 1.80
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord (2004) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Neuropathological findings in benign tremulous parkinsonism. Mov Disord (2012) 1.74
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord (2004) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Progressive supranuclear palsy: where are we now? Lancet Neurol (2002) 1.65
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain (2007) 1.52
Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord (2007) 1.52
Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations. Dev Med Child Neurol (2013) 1.51
J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology (2008) 1.50
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol (2003) 1.48
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain (2006) 1.47
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Parkinsonism secondary to neurosyphilis. Mov Disord (2008) 1.46
Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry (2012) 1.44
Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci (2009) 1.43
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain (2010) 1.43
Presurgical orthopedics has no effect on archform in unilateral cleft lip and palate. Cleft Palate Craniofac J (2011) 1.43
Opsoclonus myoclonus syndrome associated with GQ1b antibodies. Mov Disord (2012) 1.43
Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology (2010) 1.42
Natalizumab adverse events are rare in patients with multiple sclerosis. Arq Neuropsiquiatr (2013) 1.40
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Late onset ataxia: MSA-C or SCA 17? A gene penetrance dilemma. Mov Disord (2013) 1.39
Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord (2007) 1.35
Neurological manifestations in Wilson's disease: Report of 119 cases. Mov Disord (2006) 1.35
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain (2010) 1.34
Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs (2009) 1.32
Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol (2004) 1.31
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
Reliability of peer and self-assessment scores compared with trainers' scores following third molar surgery. Med Educ (2007) 1.28
The time course of retrograde trans-synaptic degeneration following occipital lobe damage in humans. Brain (2012) 1.25
Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol (2004) 1.24
T testing the immune system. Immunity (2008) 1.23
Pathophysiological differences between musician's dystonia and writer's cramp. Brain (2005) 1.23
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain (2011) 1.22
Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. Brain (2004) 1.21
The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord (2014) 1.21
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol (2006) 1.20
Statistical analyses of complex denaturing gradient gel electrophoresis profiles. J Clin Microbiol (2005) 1.18
Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. J Neurol (2012) 1.18
Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord (2008) 1.17
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain (2004) 1.16
Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol (2008) 1.15
Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord (2004) 1.14
Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. Neurobiol Aging (2007) 1.14
The effect of the new "24 hour alcohol licensing law" on the incidence of facial trauma in London. Br J Oral Maxillofac Surg (2008) 1.14
α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc Natl Acad Sci U S A (2011) 1.13